REFLECTION Study

About grail

GRAIL's mission is to alleviate the global burden of cancer through early detection. The company has achieved a leading position in the MCED space with its Galleri test, supported by a robust clinical program involving over 385,000 participants, including landmark trials like NHS-Galleri. Its strategy centers on generating definitive clinical evidence to drive widespread adoption, secure reimbursement, and integrate its test into routine clinical care for adults at elevated risk.

Therapeutic Areas